Patents by Inventor Clay B. Siegall

Clay B. Siegall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for augmenting an immune response using anti-CD40 antibodies
    Patent number: 7824683
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: December 28, 2009
    Date of Patent: November 2, 2010
    Assignee: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
  • METHODS FOR AUGMENTING AN IMMUNE RESPONSE USING ANTI-CD40 ANTIBODIES
    Publication number: 20100158906
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Application
    Filed: December 28, 2009
    Publication date: June 24, 2010
    Applicant: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, JR.
  • Methods for the treatment of cancer using anti-CD40 antibodies
    Patent number: 7666422
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: January 20, 2009
    Date of Patent: February 23, 2010
    Assignee: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
  • METHODS FOR THE TREATMENT OR PREVENTION OF IMMUNE DISORDERS USING ANTI-CD40 ANTIBODIES
    Publication number: 20090280117
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Application
    Filed: January 20, 2009
    Publication date: November 12, 2009
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, JR.
  • Methods for the treatment of cancer using anti-CD40 antibodies
    Patent number: 7510711
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: March 31, 2009
    Assignee: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
  • Methods for treating immune disorders or cancer with anti-CD40 antibodies
    Patent number: 7498032
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: March 3, 2009
    Assignee: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
  • Recombinant anti-CD40 antibody and uses thereof
    Patent number: 6946129
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: June 8, 1999
    Date of Patent: September 20, 2005
    Assignee: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
  • Methods for the treatment and prevention of cancer using anti-CD40 antibodies
    Patent number: 6843989
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 18, 2005
    Assignee: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
  • Nucleic acids encoding anti-CD40 proteins and methods of producing recombinant anti-CD40 proteins
    Patent number: 6838261
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 4, 2005
    Assignee: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
  • Methods for the treatment or prevention of immune disorders using anti-CD40 antibodies
    Publication number: 20040235074
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise, administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Application
    Filed: May 14, 2004
    Publication date: November 25, 2004
    Applicant: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell
  • Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
    Patent number: 5932447
    Abstract: The molecular cloning and expression of biologically active ribosome-inactivating protein bryodin 1 are described. A complete amino acid and oligonucleotide sequence encoding bryodin 1 are also described. Further, plasmids, expression vectors comprising a nucleotide sequence encoding bryodin 1 and transformed host cells are described. Isolation and characterization of the nucleotide sequence for bryodin 1 enables the recombinant production of large amount of bryodin 1 for use in vitro or in vivo directly or as ligand/toxin conjugates or fusion proteins. These compositions can be used to selectively kill undesired cells such as cancer cells, infected cells, bacteria and the like.
    Type: Grant
    Filed: February 7, 1996
    Date of Patent: August 3, 1999
    Assignee: Bristol-Myers Squibb Company
    Inventor: Clay B. Siegall
  • Antibodies to HER4, human receptor tyrosine kinase
    Patent number: 5811098
    Abstract: The molecular cloning, expression, and biological characteristics of a novel receptor tyrosine kinase related to the epidermal growth factor receptor, termed HER4/p180.sup.erbB4, are described. Antibodies to HER4 are disclosed. A HER4 ligand capable of inducing cellular differentiation of breast cancer cells is also disclosed. In view of the expression of HER4 in several human cancers and in certain tissues of neuronal and muscular origin, various diagnostic and therapeutic uses of HER4-derived and HER4-related biological compositions are provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 22, 1998
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gregory D. Plowman, Jean-Michel Culouscou, Mohammed Shoyab, Clay B. Siegall, Ingegerd Hellstrom, Karl E. Hellstrom
  • Bryodin 2 a ribosome-inactivating protein isolated from the plant Bryonia dioica
    Patent number: 5597569
    Abstract: The present invention discloses a new ribosome-inactivating protein, bryodin 2, isolated from the plant Bryonia dioica. This ribosome-inactivating protein (RIP) is a type IRIP having a single polypeptide chain and no cellular receptor domain. Like many type I RIPs, bryodin 2 has a molecular weight of about 27,000 daltons and a pI of 9.5. Bryodin 2 differs from previously identified ribosome-inactivating protein in its amino acid composition, amino acid sequence, and toxicity in vitro and in vivo. Bryodin 2 is useful, as are other type I ribosome-inactivating proteins, as an abortifacient, immunomodulator, anti-tumor or anti-viral agent. Compositions comprising bryodin 2 as an immunoconjugate or fusion molecule are particularly useful to kill cells of a target population.
    Type: Grant
    Filed: October 20, 1994
    Date of Patent: January 28, 1997
    Assignee: Bristol-Myers Squibb Company
    Inventors: Clay B. Siegall, Susan L. Gawlak, Hans Marquardt
  • Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
    Patent number: 5541110
    Abstract: The molecular cloning and expression of biologically active ribosome-inactivating protein bryodin 1 are described. A complete amino acid and oligonucleotide sequence encoding bryodin 1 are also described. Further, plasmids, expression vectors comprising a nucleotide sequence encoding bryodin 1 and transformed host cells are described. Isolation and characterization of the nucleotide sequence for bryodin 1 enables the recombinant production of large amount of bryodin 1 for use in vitro or in vivo directly or as ligand/toxin conjugates or fusion proteins. These compositions can be used to selectively kill undesired cells such as cancer cells, infected cells, bacteria.
    Type: Grant
    Filed: May 17, 1994
    Date of Patent: July 30, 1996
    Assignee: Bristol-Myers Squibb
    Inventor: Clay B. Siegall